Company intelligence / Profile preview

NanoValent Pharmaceuticals, Inc.

Bozeman, Montana, United Statesnanovalent.com ↗

Ownership: Private
Development stage: Other

Overview

Lead candidate NV103 (irinotecan-anti-CD99) is approaching IND status with strong data in CD99 expressing tumor models. The platform technology has shown significant enhancement of therapeutic efficacy in preclinical studies, with NV102 increasing tumor-killing efficacy 10-12 fold in vitro compared to untargeted formulations, and NV101 showing 40-fold enhancement versus commercial Doxo-liposomes.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADC)Nanoparticle-based therapeuticsLiposomal drug delivery
Industry: Biotech

Drug pipeline

5 assets

NV103

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Children's Hospital Los Angeles (CHLA)Boston University

Beyond the preview

Go deeper on NanoValent Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoValent Pharmaceuticals, Inc..

Explore the full profile